A BILL 
To amend title XXVII of the Public Health Service Act 
to require health plan oversight of pharmacy benefit 
manager services, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘PBM Transparency 
4
in Prescription Drug Costs Act’’. 
5
SEC. 2. HEALTH PLAN OVERSIGHT OF PHARMACY BENEFIT 
6
MANAGER SERVICES. 
7
Subpart II of part A of title XXVII of the Public 
8
Health Service Act (42 U.S.C. 300gg–11 et seq.) is 
9
amended by adding at the end the following: 
10
03:44 Dec 11, 2019
H5304
2 
•HR 5304 IH
‘‘SEC. 2729A. HEALTH PLAN OVERSIGHT OF PHARMACY 
1
BENEFIT MANAGER SERVICES. 
2
‘‘(a) IN GENERAL.—A group health plan or health 
3
insurance issuer offering group or individual health insur-
4
ance coverage or an entity or subsidiary providing phar-
5
macy benefits management services shall not enter into 
6
a contract with a drug manufacturer, distributor, whole-
7
saler, subcontractor, rebate aggregator, or any associated 
8
third party that limits the disclosure of information to 
9
plan sponsors in such a manner that prevents the plan 
10
or coverage, or an entity or subsidiary providing pharmacy 
11
benefits management services on behalf of a plan or cov-
12
erage from making the reports described in subsection (b). 
13
‘‘(b) REPORTS TO GROUP PLAN SPONSORS.— 
14
‘‘(1) IN
GENERAL.—Beginning with the first 
15
plan year that begins after the date of enactment of 
16
this section, not less frequently than once every six 
17
months, a health insurance issuer offering group 
18
health insurance coverage or an entity providing 
19
pharmacy benefits management services on behalf of 
20
a group health plan shall submit to the self-funded 
21
group health plan and at the request of any other 
22
group health plan a report in accordance with this 
23
subsection and make such report available to the 
24
plan sponsor in a machine-readable format. Each 
25
03:44 Dec 11, 2019
H5304
3 
•HR 5304 IH
such report shall include, with respect to the applica-
1
ble group health plan or health insurance coverage— 
2
‘‘(A) information collected from drug man-
3
ufacturers by such issuer or entity on the total 
4
amount of copayment assistance dollars paid, or 
5
copayment cards applied, that were funded by 
6
the drug manufacturer with respect to the en-
7
rollees in such plan or coverage; 
8
‘‘(B) a list of each covered drug dispensed 
9
during the reporting period, including, with re-
10
spect to each such drug during the reporting 
11
period— 
12
‘‘(i) the brand name, chemical entity, 
13
and National Drug Code; 
14
‘‘(ii) the number of enrollees for 
15
whom the drug was filled during the plan 
16
year, the total number of prescription fills 
17
for the drug (including original prescrip-
18
tions and refills), and the total number of 
19
dosage units of the drug dispensed across 
20
the plan year, including whether the dis-
21
pensing channel was by retail, mail order, 
22
or specialty pharmacy; 
23
‘‘(iii) the wholesale acquisition cost, 
24
listed as cost per days supply and cost per 
25
03:44 Dec 11, 2019
H5304
4 
•HR 5304 IH
pill, or in the case of a drug in another 
1
form, per dose; 
2
‘‘(iv) the total out-of-pocket spending 
3
by enrollees on such drug, including en-
4
rollee spending through copayments, coin-
5
surance, and deductibles; and 
6
‘‘(v) for any drug for which gross 
7
spending of the group health plan or 
8
health 
insurance 
coverage 
exceeded 
9
$10,000 during the reporting period— 
10
‘‘(I) a list of all other available 
11
drugs in the same therapeutic cat-
12
egory or class, including brand name 
13
drugs and biological products and ge-
14
neric drugs or biosimilar biological 
15
products that are in the same thera-
16
peutic category or class; and 
17
‘‘(II) the rationale for preferred 
18
formulary placement of a particular 
19
drug or drugs in that therapeutic cat-
20
egory or class; 
21
‘‘(C) a list of each therapeutic category or 
22
class of drugs that were dispensed under the 
23
health plan or health insurance coverage during 
24
the reporting period, and, with respect to each 
25
03:44 Dec 11, 2019
H5304
5 
•HR 5304 IH
such therapeutic category or class of drugs, 
1
during the reporting period— 
2
‘‘(i) total gross spending by the plan, 
3
before manufacturer rebates, fees, or other 
4
manufacturer remuneration; 
5
‘‘(ii) the number of enrollees who 
6
filled a prescription for a drug in that cat-
7
egory or class; 
8
‘‘(iii) if applicable to that category or 
9
class, a description of the formulary tiers 
10
and utilization mechanisms (such as prior 
11
authorization or step therapy) employed 
12
for drugs in that category or class; 
13
‘‘(iv) the total out-of-pocket spending 
14
by enrollees, including enrollee spending 
15
through copayments, coinsurance, and 
16
deductibles; and 
17
‘‘(v) for each therapeutic category or 
18
class under which three or more drugs are 
19
marketed and available— 
20
‘‘(I) the amount received, or ex-
21
pected to be received, from drug man-
22
ufacturers in rebates, fees, alternative 
23
discounts, or other remuneration— 
24
03:44 Dec 11, 2019
H5304
6 
•HR 5304 IH
‘‘(aa) to be paid by drug 
1
manufacturers for claims in-
2
curred during the reporting pe-
3
riod; or 
4
‘‘(bb) that is related to utili-
5
zation of drugs, in such thera-
6
peutic category or class; 
7
‘‘(II) the total net spending by 
8
the health plan or health insurance 
9
coverage on that category or class of 
10
drugs; and 
11
‘‘(III) the net price per dosage 
12
unit or course of treatment incurred 
13
by the health plan or health insurance 
14
coverage and its enrollees, after man-
15
ufacturer rebates, fees, and other re-
16
muneration for drugs dispensed within 
17
such therapeutic category or class 
18
during the reporting period; 
19
‘‘(D) total gross spending on prescription 
20
drugs by the plan or coverage during the re-
21
porting period, before rebates and other manu-
22
facturer fees or remuneration; 
23
‘‘(E) total amount received, or expected to 
24
be received, by the health plan or health insur-
25
03:44 Dec 11, 2019
H5304
7 
•HR 5304 IH
ance coverage in drug manufacturer rebates, 
1
fees, alternative discounts, and all other remu-
2
neration received from the manufacturer or any 
3
third party related to utilization of drug or 
4
drug spending under that health plan or health 
5
insurance coverage during the reporting period; 
6
‘‘(F) the total net spending on prescription 
7
drugs by the health plan or health insurance 
8
coverage during the reporting period; and 
9
‘‘(G) amounts paid directly or indirectly in 
10
rebates, fees, or any other type of remuneration 
11
to brokers, consultants, advisors, or any other 
12
individual or firm who referred the group health 
13
plan’s or health insurance issuer’s business to 
14
the pharmacy benefit manager. 
15
‘‘(2) PRIVACY REQUIREMENTS.—Health insur-
16
ance issuers offering group health insurance cov-
17
erage and entities providing pharmacy benefits man-
18
agement services on behalf of a group health plan 
19
shall provide information under paragraph (1) in a 
20
manner consistent with the privacy, security, and 
21
breach notification regulations promulgated under 
22
section 264(c) of the Health Insurance Portability 
23
and Accountability Act of 1996 (or successor regula-
24
tions), and shall restrict the use and disclosure of 
25
03:44 Dec 11, 2019
H5304
8 
•HR 5304 IH
such information according to such privacy regula-
1
tions. 
2
‘‘(3) DISCLOSURE AND REDISCLOSURE.— 
3
‘‘(A) LIMITATION
TO
BUSINESS
ASSOCI-
4
ATES.—A group health plan receiving a report 
5
under paragraph (1) may disclose such informa-
6
tion only to business associates of such plan as 
7
defined in section 160.103 of title 45, Code of 
8
Federal Regulations (or successor regulations). 
9
‘‘(B) CLARIFICATION REGARDING PUBLIC 
10
DISCLOSURE
OF
INFORMATION.—Nothing in 
11
this section prevents a health insurance issuer 
12
offering group health insurance coverage or an 
13
entity providing pharmacy benefits management 
14
services on behalf of a group health plan from 
15
placing reasonable restrictions on the public dis-
16
closure of the information contained in a report 
17
described in paragraph (1). 
18
‘‘(c) LIMITATIONS ON SPREAD PRICING.— 
19
‘‘(1) PASS-THROUGH OFFERING TO PLAN.—A 
20
designated plan administrator of an applicable self- 
21
insured health plan, or an entity providing pharmacy 
22
benefit management services to such health plan 
23
shall offer at least one contractual arrangement that 
24
does not charge the plan or enrollee, a price for a 
25
03:44 Dec 11, 2019
H5304
9 
•HR 5304 IH
prescription drug that exceeds the price paid to the 
1
pharmacy, excluding penalties or fees paid by phar-
2
macies to such plan, issuer, or entity. 
3
‘‘(2) DEFAULT TO PASS-THROUGH PRICING.— 
4
For purposes of paragraph (1), a designated plan 
5
administrator of an applicable self-insured health 
6
plan, or an entity providing pharmacy benefit man-
7
agement services to such health plan shall not 
8
charge the plan or enrollee an amount for a 
9
presciption drug that exceeds the price paid to the 
10
pharmacy, excluding penalties paid by pharmacies to 
11
such plan or entity, without the express permission 
12
of the health plan sponsor. 
13
‘‘(3) SUPPLEMENTARY REPORTING FOR INTRA- 
14
COMPANY PRESCRIPTION DRUG TRANSACTIONS.—A 
15
health insurance issuer of group health insurance 
16
coverage or an entity providing pharmacy benefits 
17
management services under a group health plan or 
18
group health insurance coverage that conducts 
19
transactions with a wholly or partially owned phar-
20
macy, as described in paragraph (2), shall submit, 
21
together with the report under subsection (b), a sup-
22
plementary quarterly report to the plan sponsor that 
23
includes— 
24
03:44 Dec 11, 2019
H5304
10 
•HR 5304 IH
‘‘(A) an explanation of any benefit design 
1
parameters that encourage enrollees in the plan 
2
or coverage to fill prescriptions at mail order, 
3
specialty, or retail pharmacies that are wholly 
4
or partially owned by that issuer or entity; 
5
‘‘(B) the percentage of total prescriptions 
6
charged to the plan, coverage, or enrollees in 
7
the plan or coverage, that were dispensed by 
8
mail order, specialty, or retail pharmacies that 
9
are wholly or partially owned by the issuer or 
10
entity providing pharmacy benefits management 
11
services; and 
12
‘‘(C) a list of all drugs dispensed by such 
13
wholly or partially owned pharmacy and 
14
charged to the plan or coverage, or enrollees of 
15
the plan or coverage, during the applicable 
16
quarter, and, with respect to each drug— 
17
‘‘(i) the amount charged per dosage 
18
unit or course of treatment with respect to 
19
enrollees in the plan or coverage, including 
20
amounts charged to the plan or coverage 
21
and amounts charged to the enrollee; 
22
‘‘(ii) the median amount charged to 
23
the plan or coverage, per dosage unit or 
24
course 
of 
treatment, 
and 
including 
25
03:44 Dec 11, 2019
H5304
11 
•HR 5304 IH
amounts paid by the enrollee, when the 
1
same drug is dispensed by other phar-
2
macies that are not wholly or partially 
3
owned by the issuer or entity and that are 
4
included in the pharmacy network of that 
5
plan or coverage; 
6
‘‘(iii) the interquartile range of the 
7
costs, per dosage unit or course of treat-
8
ment, and including amounts paid by the 
9
enrollee, when the same drug is dispensed 
10
by other pharmacies that are not wholly or 
11
partially owned by the issuer or entity and 
12
that are included in the pharmacy network 
13
of that plan or coverage; and 
14
‘‘(iv) the lowest cost per dosage unit 
15
or course of treatment, for such drug, in-
16
cluding amounts charged to the plan or 
17
issuer and enrollee, that is available from 
18
any pharmacy included in the network of 
19
the plan or coverage. 
20
‘‘(d) FULL REBATE PASS-THROUGH TO PLAN.— 
21
‘‘(1) IN GENERAL.—A pharmacy benefits man-
22
ager, a third-party administrator of a group health 
23
plan, a health insurance issuer offering group health 
24
insurance coverage, or an entity providing pharmacy 
25
03:44 Dec 11, 2019
H5304
12 
•HR 5304 IH
benefits management services under such health 
1
plan or health insurance coverage shall remit 100 
2
percent of rebates, fees, alternative discounts, and 
3
all other remuneration received from a pharma-
4
ceutical manufacturer, distributor or any other third 
5
party, that are related to utilization of drugs under 
6
such health plan or health insurance coverage, to the 
7
health plan issuer. 
8
‘‘(2) FORM AND MANNER OF REMITTANCE.— 
9
Such rebates, fees, alternative discounts, and other 
10
remuneration shall be— 
11
‘‘(A) remitted to the group health plan in 
12
a timely fashion after the period for which such 
13
rebates, fees, or other remuneration is cal-
14
culated, and in no case later than 120 days 
15
after the end of such period; 
16
‘‘(B) fully disclosed and enumerated to the 
17
group health plan sponsor, as described in 
18
(b)(1); 
19
‘‘(C) available for audit by the plan spon-
20
sor, or a third party designated by a plan spon-
21
sor no less than once per plan year; and 
22
‘‘(D) returned to the issuer or entity pro-
23
viding 
pharmaceutical 
benefit 
management 
24
services by the group health plan if audits by 
25
04:56 Dec 12, 2019
H5304
13 
•HR 5304 IH
such issuer or entity indicate that the amounts 
1
received are incorrect after such amounts have 
2
been paid to the group health plan. 
3
‘‘(3) AUDIT OF REBATE CONTRACTS.—A phar-
4
macy benefits manager, a third-party administrator 
5
of a group health plan, a health insurance issuer of-
6
fering a group health insurance coverage, or an enti-
7
ty providing pharmacy benefits management services 
8
under such health plan or health insurance coverage 
9
shall make rebate contracts with drug manufactur-
10
ers available for audit by such plan sponsor or des-
11
ignated third party, subject to confidentiality agree-
12
ments to prevent re-disclosure of such contracts. 
13
‘‘(e) ENFORCEMENT.— 
14
‘‘(1) IN GENERAL.—The Secretary, in consulta-
15
tion with the Secretary of Labor and the Secretary 
16
of the Treasury, shall enforce this section. 
17
‘‘(2) FAILURE TO PROVIDE TIMELY INFORMA-
18
TION.—A health insurance issuer or an entity pro-
19
viding pharmacy benefit management services that 
20
violates subsection (a), fails to provide information 
21
required under subsection (b), engages in spread 
22
pricing as defined in subsection (c), or fails to com-
23
ply with the requirements of subsection (d), or a 
24
drug manufacturer that fails to provide information 
25
03:44 Dec 11, 2019
H5304
14 
•HR 5304 IH
under subsection (b)(1)(A), in a timely manner shall 
1
be subject to a civil monetary penalty in the amount 
2
of $10,000 for each day during which such violation 
3
continues or such information is not disclosed or re-
4
ported. 
5
‘‘(3) FALSE INFORMATION.—A health insurance 
6
issuer, entity providing pharmacy benefit manage-
7
ment services, or drug manufacturer that knowingly 
8
provides false information under this section shall be 
9
subject to a civil money penalty in an amount not 
10
to exceed $100,000 for each item of false informa-
11
tion. Such civil money penalty shall be in addition to 
12
other penalties as may be prescribed by law. 
13
‘‘(4) PROCEDURE.—The provisions of section 
14
1128A of the Social Security Act, other than sub-
15
sections (a) and (b) and the first sentence of sub-
16
section (c)(1) of such section shall apply to civil 
17
monetary penalties under this subsection in the 
18
same manner as such provisions apply to a penalty 
19
or proceeding under section 1128A of the Social Se-
20
curity Act. 
21
‘‘(5) SAFE HARBOR.—The Secretary may waive 
22
penalties under paragraph (2), or extend the period 
23
of time for compliance with a requirement of this 
24
section, for an entity in violation of this section that 
25
04:56 Dec 12, 2019
H5304
15 
•HR 5304 IH
has made a good-faith effort to comply with this sec-
1
tion. 
2
‘‘(f) RULE OF CONSTRUCTION.—Nothing in this sec-
3
tion shall be construed to prohibit entities providing phar-
4
macy benefits management services from retaining bona 
5
fide service fees, provided that such fees are transparent 
6
to group health plans and health insurance issuers and 
7
are not linked directly to the price or formulary placement 
8
or position of a drug. 
9
‘‘(g) DEFINITIONS.—In this section— 
10
‘‘(1) the term ‘similarly situated pharmacy’ 
11
means, with respect to a particular pharmacy, an-
12
other pharmacy that is approximately the same size 
13
(as measured by the number of prescription drugs 
14
dispensed), and that serves patients in the same geo-
15
graphical area, whether through physical locations or 
16
mail order; 
17
‘‘(2) the term ‘wholesale acquisition cost’ has 
18
the 
meaning 
given 
such 
term 
in 
section 
19
1847A(c)(6)(B) of the Social Security Act; and 
20
‘‘(3) the term ‘bona fide service fees’ means 
21
fees paid by a manufacturer, customer, or client 
22
(other than a group health plan or health insurance 
23
issuer) of an entity providing pharmacy benefit man-
24
agement services, to an entity providing pharmacy 
25
03:44 Dec 11, 2019
H5304
16 
•HR 5304 IH
benefit management services, that represent fair 
1
market value for bona fide, itemized services actually 
2
performed on behalf of the manufacturer, customer, 
3
or client would otherwise perform or contract for in 
4
the absence of the service arrangement, without 
5
prior consent for any specific arrangements.’’. 
6
SEC. 3. THIRD-PARTY ADMINISTRATORS. 
7
Any obligation on a third-party administrator under 
8
this Act (including the amendment made by this Act) shall 
9
not affect any other direct or indirect requirement under 
10
any other provision of Federal law that applies to third- 
11
party administrators offering services to group health 
12
plans. 
13
Æ 
03:44 Dec 11, 2019
H5304
